US 11,873,308 B2
Biologically active taxane analogs and methods of treatment by oral administration
James D. McChesney, Etta, MS (US); Gilles H. Tapolsky, Louisville, KY (US); David Lloyd Emerson, Longmont, CO (US); John Marshall, Washington, DC (US); Michael Kurman, Upper Saddle River, NJ (US); and Manuel R. Modiano, Tucson, AZ (US)
Assigned to Tapestry Pharmaceuticals, Inc., Altanta, GA (US)
Filed by Tapestry Pharmaceuticals, Inc., Atlanta, GA (US)
Filed on Dec. 1, 2021, as Appl. No. 17/539,578.
Application 17/539,578 is a continuation of application No. 16/929,719, filed on Jul. 15, 2020, granted, now 11,220,512.
Application 16/929,719 is a continuation of application No. 16/569,302, filed on Sep. 12, 2019, granted, now 10,745,408, issued on Aug. 18, 2020.
Application 16/569,302 is a continuation of application No. 15/797,145, filed on Oct. 30, 2017, granted, now 10,450,323, issued on Oct. 22, 2019.
Application 15/797,145 is a continuation of application No. 13/950,316, filed on Jul. 25, 2013, granted, now 9,802,951, issued on Oct. 31, 2017.
Application 13/950,316 is a continuation of application No. 13/620,852, filed on Sep. 15, 2012, granted, now 8,552,056, issued on Oct. 8, 2013.
Application 13/620,852 is a continuation of application No. 12/873,477, filed on Sep. 1, 2010, granted, now 8,273,789, issued on Sep. 25, 2012.
Application 12/873,477 is a continuation of application No. 12/593,153, previously published as PCT/US2008/055384, filed on Feb. 28, 2008.
Claims priority of provisional application 60/911,607, filed on Apr. 13, 2007.
Claims priority of provisional application 60/908,459, filed on Mar. 28, 2007.
Prior Publication US 2022/0089606 A1, Mar. 24, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/357 (2006.01); C07D 493/06 (2006.01); A61K 31/495 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01)
CPC C07D 493/06 (2013.01) [A61K 31/357 (2013.01); A61K 31/495 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01)] 22 Claims
OG exemplary drawing
 
1. A method for the treatment of cancer in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a compound of Formula (1):

OG Complex Work Unit Chemistry
wherein the cancer is selected from the group consisting of astrocytoma, cranipharyngioma, glioma, ependymoma, neuroglioma, oligodendroglioma, glioblastoma multiforme, meningioma, medulloblastoma, and a primitive neuroectoderm.